Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec:72:101490.
doi: 10.1016/j.arr.2021.101490. Epub 2021 Oct 17.

Reply to "Caution in underrepresentation of older adults in clinical trials on COVID-19 vaccines"

Nicola Veronese  1 , Mirko Petrovic  2 , Athanase Benetos  3 , Michael Denkinger  4 , Adalsteinn Gudmundsson  5 , Wilma Knol  6 , Christine Marking  7 , George Soulis  8 , Stefania Maggi  9 , Antonio Cherubini  10 ; special interest group in Systematic Reviews and Meta-analyses and the task force on Pharmaceutical strategy of the European Geriatric Medicine Society (EuGMS)
Affiliations
Comment

Reply to "Caution in underrepresentation of older adults in clinical trials on COVID-19 vaccines"

Nicola Veronese et al. Ageing Res Rev. 2021 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Veronese N., Petrovic M., Benetos A., Denkinger M., Gudmundsson A., Knol W., Marking C., Soulis G., Maggi S., Cherubini A. Underrepresentation of older adults in clinical trials on COVID-19 vaccines: a systematic review. Ageing Res. Rev. 2021;71 - PMC - PubMed
    1. Xia S., Duan K., Zhang Y., Zhao D., Zhang H., Xie Z., Li X., Peng C., Zhang Y., Zhang W. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324:951–960. - PMC - PubMed
    1. Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G.F., Tan W., Wu G., Xu M., Lou Z. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021;21:39–51. - PMC - PubMed
    1. Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K., Han W., Chen Z., Tang R., Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181–192. - PMC - PubMed
    1. Zhu F.-C., Guan X.-H., Li Y.-H., Huang J.-Y., Jiang T., Hou L.-H., Li J.-X., Yang B.-F., Wang L., Wang W.-J. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. - PMC - PubMed

Substances